Does Retatrutide Cause More Nausea than Tirzepatide?

Yes, retatrutide appears to cause more nausea than tirzepatide based on early clinical trial data. Retatrutide's triple-hormone approach (GLP-1, GIP, and glucagon receptor agonist) creates more gastrointestinal side effects, with nausea rates reaching 50-60% in Phase 2 trials compared to tirzepatide's 20-30% nausea incidence. The additional glucagon pathway stimulation in retatrutide contributes to increased gastric motility changes and digestive disruption. Most patients experience peak nausea during the first 4-6 weeks of treatment as their body adjusts to the medication. We can help you compare these medications and discuss nausea management strategies to find the most tolerable weight loss approach for your situation.